Abstract:BackgroundYes-associated protein 1 (YAP1) is an effector of Hippo pathway, which is critical for regulating organ size, cell proliferation and tumor growth in mammals. Many previous studies have explored the relationship between YAP1 and various types of cancer. However, these studies were limited by the small samples size and the findings were inconsistent among them. Therefore, a meta-analysis was conducted to assess the association between YAP1 and malignancies.MethodsA systematic literature search was conducted for eligible studies in the PubMed, Corchane Library, Web of Knowledge, EMBASE and CBM disc databases from inception to August 1st 2014. After heterogeneity analysis, pooled harzad ratio (HR) with 95% confidence interval (95% CI) using both fixed and random effect models were estimated in STATA 10.0. Meta regression analysis, subgroup analysis and sensitivity analysis were performed to explore the potential sources of heterogeneity and to evaluate the robustness of the result. Publication bias was assessed by Egger's test and funnel plot.ResultsA total of 21 unique articles from 2009 to 2014, comprising 2983 patients, were analyzed in the meta-analysis. The association of YAP1 expression and overall survival time (OS) was evaluated in 20 studies including 2067 patients. Positive YAP1 showed poorer OS (HR = 1.826; 95% CI = 1.465-2.275; p < 0.002). For evaluating disease-free survival time (DFS), 10 studies with 1139 patients were analyzed. Positive YAP1 indicated worse DFS (HR = 2.114; 95% CI = 1.406-3.179; p < 0.001). Subgroup analysis showed that both positive nuclear YAP1 (HR = 1.390, 95% CI: 0.810-2.400, p = 0.729) and up-regulation overall YAP1 (HR = 2.237, 95% CI: 1.548-3.232, p < 0.001) had poorer OS for patients with malignancies. Similarly, both positive nuclear YAP1 (HR = 3.733, 95% CI: 1.469-9.483, p = 0.001) and up-regulation overall YAP1 (HR = 1.481, 95% CI: 1.163-1.886, p = 0.554) showed worse DFS. The patients with urogenital system cancer had the poorest OS (HR = 2.133, 95% CI: 1.549-2.937, p = 0.020). The patients with alimentary system cancer had the most significant impact on DFS (HR = 1.879, 95% CI: 1.537-2.297, p < 0.001).ConclusionBoth overall and nuclear YAP1 overexpression are intimately associated with adverse OS and DFS in numerous cancers, suggesting that YAP1 may act as a potential therapeutic targets of these malignancies in the future.

High Expression of Yes-activated Protein-1 in Papillary Thyroid Carcinoma Correlates With Poor Prognosis.

Yes-associated Protein 1 Promotes Papillary Thyroid Cancer Cell Proliferation by Activating the ERK/MAPK Signaling Pathway

A Potential Role for the Hippo Pathway Protein, Yap, in Controlling Proliferation, Cell Cycle Progression, and Autophagy in Bcpap and Ki Thyroid Papillary Carcinoma Cells

Clinical and Prognostic Significance of Yes-associated Protein in Colorectal Cancer

Prognostic Value Of Yes-Associated Protein 1 (Yap1) In Various Cancers: A Meta-Analysis

High Cytoplasmic YAP1 Expression Predicts a Poor Prognosis in Patients with Colorectal Cancer

Overexpression of Yes-Associated Protein Contributes to Progression and Poor Prognosis of Non-Small-cell Lung Cancer.

Abstract PO3-28-06: YAP1 expression is a good prognostic marker of hormone receptor-positive HER2-negative breast cancer: clinicopathologic analysis using the 21-gene recurrent score

Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues

Yes-associated Protein Expression in Paired Primary and Local Recurrent Breast Cancer and Its Clinical Significance

AP-2α Expression in Papillary Thyroid Carcinoma Predicts Tumor Progression and Poor Prognosis

Loss of Yes-associated Protein Represents an Aggressive Subtype of Colorectal Cancer

The Prognostic Value of YAP1 on Clinical Outcomes in Human Cancers

Clinical Significance of Yes-associated Protein 1 in Esophageal Squamous Cell Carcinoma

YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

Yes-associated Protein Expression is Associated with Poor Prognosis in Patients with Colorectal Cancer

Expression of yes-associated protein 1 in prostate cancer and its clinicopathological significance

Amyloid Precursor Protein As A Potential Marker Of Malignancy And Prognosis In Papillary Thyroid Carcinoma

YAP1 Mutation As a Novel Predictor of Response to Anti-Pd-1/pd-l1 Treatment in Pan-Cancers.

Relationship between Yes-Associated Protein 1 and Prognosis of Digestive System Neoplasm: Quantitative Analysis and Bioinformatics Analysis Based on 4023 Patients

Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features.